Skip to main content
Clinical Trials/NCT02615496
NCT02615496
Completed
Not Applicable

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study

Bayer0 sites716 target enrollmentDecember 7, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Macular Degeneration
Sponsor
Bayer
Enrollment
716
Primary Endpoint
The proportion of physicians with accurate knowledge and understanding of key safety information (identified risks and prescribing behaviors) contained in the Eylea educational materials as assessed by a study specific questionnaire.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.

Registry
clinicaltrials.gov
Start Date
December 7, 2015
End Date
January 31, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Physicians eligibility:
  • Licensed and practicing ophthalmologist
  • Prescribed and administered aflibercept to at least one patient in the past 6 months
  • Patients eligibility:
  • Patient has been administered aflibercept at least once within the last 6 months for any indication and is returning for a subsequent visit.
  • Patient is aged 18 years or older.
  • Patient is able to understand and sign the consent form and patient questionnaire.
  • Patient can understand the native language of the country in which the study is being conducted.
  • Patient has not participated in a clinical trial for the treatment of an aflibercept indication (e.g., wAMD, CRVO, or DME) in the past 12 months.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The proportion of physicians with accurate knowledge and understanding of key safety information (identified risks and prescribing behaviors) contained in the Eylea educational materials as assessed by a study specific questionnaire.

Time Frame: Up to 2 years

The proportion of patients with accurate knowledge and understanding of key safety information (identified risks and guidelines) contained in the Eylea educational materials as assessed by a study specific interviewer administered questionnaire.

Time Frame: Up to 2 years

Similar Trials